[1]张曦,黄瑞昊.嵌合抗原受体T细胞治疗血液肿瘤的发展与应用[J].第三军医大学学报,2019,41(23):2261-2266.
 ZHANG Xi,HUANG Ruihao.Clinical application of CAR-T cells in treatment of hematologic malignancies[J].J Third Mil Med Univ,2019,41(23):2261-2266.
点击复制

嵌合抗原受体T细胞治疗血液肿瘤的发展与应用(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第23期
页码:
2261-2266
栏目:
专题报道
出版日期:
2019-12-15

文章信息/Info

Title:
Clinical application of CAR-T cells in treatment of hematologic malignancies
作者:
张曦黄瑞昊
400037 重庆,陆军军医大学(第三军医大学)第二附属医院血液病医学中心,全军血液病中心,创伤、烧伤与复合伤研究国家重点实验室
Author(s):
ZHANG Xi HUANG Ruihao

State Key Laboratory of Trauma, Burns and Combined Injury, Medical Center of Hematology, PLA Center for Hematology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China

关键词:
嵌合抗原受体血液肿瘤白血病淋巴瘤多发性骨髓瘤炎症因子
Keywords:
chimeric antigen receptor hematologic neoplasms leukemia lymphoma multiple myeloma inflammatory cytokines
分类号:
201907013
文献标志码:
A
摘要:

目的嵌合抗原受体T细胞(chimeric antigen receptor T cell,CAR-T细胞)疗法对复发难治(relapse or recurrent,R/R)B细胞急性淋巴白血病的显著效果为R/R恶性血液肿瘤的治疗带来了希望。世界各大医院都以进一步提升CAR-T疗效和扩大其受益范围为目的,开展了针对CAR-T细胞结构、配套疗法及毒副作用管理措施的临床实验。目前,在嵌合抗原受体(CAR)结构设计优化、临床使用有效性及安全性提升和促进CAR-T细胞转归续存等方面都有长足进展,CAR-T细胞疗法临床运用的流程渐渐清晰,针对并发症的有效应对手段也逐渐丰富。但是在对某些疾病(如急性髓系白血病)的探索中,也不乏结果不尽如人意的临床研究,这为CAR-T疗法的进一步发展提出了挑战。面对这些挑战,需从制备到临床运用的各个角度出发,分析成败的原因,不断改进优化,才能最终把握成败。本文就近年来CAR-T细胞疗法在血液恶性肿瘤治疗中的发展动向及走向与临床亟需解决的问题一一梳理,并做出展望。

Abstract:

The stunning benefits of chimeric antigen receptor T (CAR-T) cell therapy in treatment of relapsed and/or refractory (R/R) B cell acute lymphoblastic leukemia have brought hope to the patients with R/R hematologic malignancies. With the aims of achieving more effective and more accessible CAR-T cell therapy, large-scale hospitals all over the world have launched clinical trails by adjusting the CAR structure, complementary treatment and management of side-effects. Great progresses had been made in the CAR structure optimization, efficiency and safety of clinical application, and transformation and survival of CAR-T cells. The process of clinical application of CAR-T cell therapy is gradually clear, and the effective measures for complications are gradually enriched. However, there still are some disappointing outcomes from clinical trails aimed at acute myeloblastic leukemia (AML), which are the challenges badly in need of solutions. In order to finally grasp the success or failure, we must analyze the causes in multiple aspects, from preparation to clinical application, and continuously improve and optimize. In this paper, we sorted out the development trend of CAR-T cell therapy and problems needing be urgently solved in the treatment of hematological malignancies in recent years, and made the prospect for the future.

参考文献/References:

[1]GROSS G, WAKS T, ESHHAR Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J]. Proc Natl Acad Sci U S A, 1989, 86(24): 10024-10028. DOI:10.1073/pnas.86.24.10024.
[2]KAWALEKAR O U, O’CONNOR R S, FRAIETTA J A, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells[J]. Immunity, 2016, 44(2): 380-390. DOI:10.1016/j.immuni.2016.01.021.
[3]LONG A H, HASO W M, SHERN J F, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors[J]. Nat Med, 2015, 21(6): 581-590. DOI:10.1038/nm.3838.
[4]RAMOS C A, ROUCE R, ROBERTSON C S, et al. In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin’s lymphomas[J]. Mol Ther, 2018, 26(12): 2727-2737. DOI:10.1016/j.ymthe.2018.09.009.
[5]ENBLAD G, KARLSSON H, GAMMELGRD G, et al. A phase Ⅰ/Ⅱa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia[J]. Clin Cancer Res, 2018, 24(24): 6185-6194. DOI:10.1158/1078-0432.CCR-18-0426.
[6]GUEDAN S, POSEY A D Jr, SHAW C, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation[J]. JCI Insight, 2018, 3(1): 96976. DOI:10.1172/jci.insight.96976.
[7]ZHANG X, LU X, YANG J, et al. Efficacy and safety of CD19 chimeric antigen receptor (CAR) T cell therapy for B-cell acute lymphocytic leukemia (B-cell aLL) in a large cohort including patients with extramedullary disease(EMD), high leukemia burden, BCR-ABL (+) mutation,TP53 mutation, and post-transplant relapse[J]. Blood, 2018,132(Suppl 1):280. DOI:10.1182/blood-2018-99-115642.
[8]LIU J, ZHONG J F, ZHANG X, et al. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies[J]. J Hematol Oncol, 2017, 10(1): 35. DOI:10.1186/s13045-017-0405-3.
[9]HOFMANN S, SCHUBERT M L, WANG L, et al. Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML)[J]. J Clin Med, 2019, 8(2): E200. DOI:10.3390/jcm8020200.
[10]HIRAYAMA A V, GAUTHIER J, HAY K A, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells[J]. Blood, 2019, 133(17): 1876-1887. DOI:10.1182/blood-2018-11-887067.
[11]HAY K A. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy[J]. Br J Haematol, 2018, 183(3): 364-374. DOI:10.1111/bjh.15644.
[12]ANAND K, BURNS E, SANO D, et al. Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS[J]. J Clin Oncol, 2019, 37(15_suppl): 2540. DOI:10.1200/jco.2019.37.15_suppl.2540.
[13]CHEN F, TEACHEY D T, PEQUIGNOT E, et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy[J]. J Immunol Methods, 2016, 434: 1-8. DOI:10.1016/j.jim.2016.03.005.
[14]STERNER R M, SAKEMURA R, COX M J, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts[J]. Blood, 2019, 133(7): 697-709. DOI:10.1182/blood-2018-10-881722.
[15]KADAUKE S, MAUDE S, GLADNEY W, et al. Early administration of tocilizumab (Toci) for the prevention of grade 4 cytokine release syndrome (CRS) after CD19-directed CAR T-cell therapy (CTL019)[J]. Cytotherapy, 2019, 21(5): e2-e3. DOI:10.1016/j.jcyt.2019.04.009.
[16]NORELLI M, CAMISA B, BARBIERA G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells[J]. Nat Med, 2018, 24(6): 739-748. DOI:10.1038/s41591-018-0036-4.
[17]PARK J H, RIVIRE I, GONEN M, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia[J]. New Engl J Med, 2018,378(5):449-459. DOI:10.1056/NEJMoa1709919.
[18]HAMIEH M, DOBRIN A, CABRIOLU A, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape[J]. Nature, 2019, 568(7750): 112-116. DOI:10.1038/s41586-019-1054-1.
[19]LIN J K, MUFFLY L S, SPINNER M A, et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma[J]. J Clin Oncol, 2019, 37(24): 2105-2119. DOI:10.1200/JCO.18.02079.
[20]MESTERMANN K, GIAVRIDIS T, WEBER J, et al. The tyrosine kinase inhibitor dasatinib Acts as a pharmacologic on/off switch for CAR T cells[J]. Sci Transl Med, 2019, 11(499): eaau5907. DOI:10.1126/scitranslmed.aau5907.

相似文献/References:

[1]李德志,周一兵,万久庆,等.全身照射用于造血干细胞移植前预处理78例临床分析[J].第三军医大学学报,2009,31(03):254.
 LI De-zhi,ZHOU Yi-bing,WAN Jiu-qing,et al.Total body irradiation before hematopoietic blood stem cells transplantation: clinical analysis of 78 cases[J].J Third Mil Med Univ,2009,31(23):254.
[2]刘林,陈幸华,张曦,等.外周血造血干细胞移植治疗儿童血液肿瘤的初期疗效观察[J].第三军医大学学报,2002,24(11):0.[doi:10.16016/j.1000-5404.2002.11.024 ]
 LIU Lin,CHEN Xing hua,ZHANG Xi,et al.[J].J Third Mil Med Univ,2002,24(23):0.[doi:10.16016/j.1000-5404.2002.11.024 ]

更新日期/Last Update: 2019-12-09